HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Edward F McKone Selected Research

ivacaftor drug combination tezacaftor

1/2021A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation.
1/2021Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial.
1/2021Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.
1/2021Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease.
1/2021A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele.
11/2019Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
10/2018VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
10/2018VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
11/2017Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Edward F McKone Research Topics

Disease

42Cystic Fibrosis (Mucoviscidosis)
01/2022 - 06/2002
6Lung Diseases (Lung Disease)
10/2021 - 08/2006
5Inflammation (Inflammations)
11/2022 - 01/2017
5Infections
12/2021 - 01/2017
2Pseudomonas Infections
10/2021 - 08/2006
1Virus Diseases (Viral Diseases)
11/2022
1Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive)
01/2022
1Psychotic Disorders (Schizoaffective Disorder)
01/2022
1Bronchiectasis
12/2021
1COVID-19
10/2020
1Malnutrition (Nutritional Deficiencies)
01/2020
1Persistent Infection
01/2020
1Lung Injury
08/2006
1Adrenal Insufficiency (Adrenal Gland Hypofunction)
11/2002
1Neoplasms (Cancer)
11/2002
1Weight Loss (Weight Reduction)
11/2002
1Acquired Immunodeficiency Syndrome (AIDS)
11/2002

Drug/Important Bio-Agent (IBA)

19ivacaftorIBA
01/2022 - 11/2011
16Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA
01/2022 - 05/2003
9ivacaftor drug combination tezacaftorIBA
01/2021 - 11/2017
8elexacaftorIBA
01/2022 - 10/2018
8ChloridesIBA
12/2021 - 09/2015
4Anti-Bacterial Agents (Antibiotics)IBA
11/2022 - 01/2020
4tezacaftorIBA
01/2022 - 11/2017
2Biomarkers (Surrogate Marker)IBA
11/2022 - 10/2021
2CytokinesIBA
01/2021 - 04/2020
2AnionsIBA
04/2019 - 01/2018
2lumacaftorIBA
01/2017 - 01/2015
1C-Reactive ProteinIBA
11/2022
1Oxygen (Dioxygen)IBA
10/2021
1Azithromycin (Zithromax)FDA LinkGeneric
10/2021
1dornase alfa (Pulmozyme)FDA Link
01/2021
1Interleukin-17 (Interleukin 17)IBA
01/2021
1tocilizumab (atlizumab)FDA Link
10/2020
1InterferonsIBA
04/2020
1EnzymesIBA
01/2020
1Expectorants (Mucolytics)IBA
01/2020
1ChemokinesIBA
01/2020
1VX-659IBA
10/2018
1Macrophage Migration-Inhibitory FactorsIBA
11/2017
1AztreonamFDA LinkGeneric
11/2017
1Lysine (L-Lysine)FDA Link
11/2017
1Pharmaceutical PreparationsIBA
11/2014
1Phenobarbital (Luminal)FDA Link
08/2009
1AndrogensIBA
12/2008
1Glutathione (Reduced Glutathione)IBA
08/2006
1Oxidants (Oxidizing Agents)IBA
08/2006
1Glutamate-Cysteine LigaseIBA
08/2006
1Megestrol Acetate (Borea)FDA LinkGeneric
11/2002
1Lactic Acid (Lactate)FDA LinkGeneric
06/2002

Therapy/Procedure

10Therapeutics
10/2021 - 11/2002
2Lung Transplantation
10/2021 - 01/2019
1Aftercare (After-Treatment)
12/2021
1High-Protein Diet
01/2020